Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Proteomics01:33

Proteomics

A proteome is the entire set of proteins that a cell type produces. We can study proteomes using the knowledge of genomes because genes code for mRNAs, and the mRNAs encode proteins. Although mRNA analysis is a step in the right direction, not all mRNAs are translated into proteins.
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential interaction between exogenous anabolic steroids and sugammadex: failed reversal of rocuronium in a patient taking testosterone and trestolone acetate.

Anaesthesia reports·2023
Same author

Understanding glomerular diseases through proteomics.

Expert review of proteomics·2021
Same author

Urinary peptidome analyses for the diagnosis of chronic kidney disease in dogs.

Veterinary journal (London, England : 1997)·2019
Same author

Urine peptidomic biomarkers for diagnosis of patients with systematic lupus erythematosus.

Lupus·2017
Same author

[Proteome analysis of undiluted vitreous humor in patients with branch retinal vein occlusion].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·2017
Same author

Beneficial Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients with Type 2 Diabetes Mellitus: Analysis of Responders and Non-Responders.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2016
Same journal

Intrinsic capacity and the trajectory of ischemic heart disease and its complications: the mediating role of insulin resistance indices.

Maturitas·2026
Same journal

Mobility limitation trajectories and longitudinal changes in delayed recall in midlife and later life: A multicohort study.

Maturitas·2026
Same journal

Digital twins in menopause: a roadmap for integrating endocrine dynamics, multisystem physiology, and precision medicine.

Maturitas·2026
Same journal

Testosterone therapy in women: Keeping pace with the evidence.

Maturitas·2026
Same journal

Diagnosis and management of androgen excess presenting after menopause.

Maturitas·2026
Same journal

Domain-specific severity of menopausal symptoms and emotional eating in midlife women.

Maturitas·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Clinical proteomics: current techniques and potential applications in the elderly.

J Siwy1, A Vlahou, L U Zimmerli

  • 1mosaiques diagnostics GmbH, Mellendorfer Str. 7-9, D-30625 Hannover, Germany.

Maturitas
|November 30, 2010
PubMed
Summary
This summary is machine-generated.

Clinical proteomics offers new biomarkers for aging and chronic diseases. Proper study design and technology are crucial for reliable results in disease management.

More Related Videos

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
11:49

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Published on: August 28, 2021

Related Experiment Videos

Last Updated: Jun 6, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue
11:49

Quantitative Proteomics Workflow using Multiple Reaction Monitoring Based Detection of Proteins from Human Brain Tissue

Published on: August 28, 2021

Area of Science:

  • Biomarker discovery
  • Proteomics
  • Aging research

Background:

  • Aging in Western societies correlates with chronic diseases like cardiovascular disease, diabetic nephropathy, and cancer.
  • There is a critical need for novel biomarkers to manage these age-related conditions effectively.
  • Advancements in proteomic analysis offer new possibilities for biomarker identification.

Purpose of the Study:

  • To review proteomic platform technologies and study design considerations for biomarker discovery.
  • To explore the application of clinical proteomics in understanding aging and age-related diseases.
  • To highlight the importance of rigorous methodology in generating reliable proteomic data.

Main Methods:

  • Review of major proteomic platform technologies, including their strengths and weaknesses.
  • Critical evaluation of proteomic study design aspects: specimen selection, data processing, and mining.
  • Analysis of physiological age-related proteome alterations and their comparison to chronic disease changes.
  • Examination of recent clinical proteomics studies with sound designs and validation in blinded cohorts.

Main Results:

  • Proteomic technologies have advanced significantly, enabling detailed analysis of the human proteome.
  • Age-related proteomic changes share similarities with indolent alterations seen in chronic diseases, particularly kidney diseases.
  • Recent studies demonstrate the potential of well-designed proteomic research in aging and disease.

Conclusions:

  • Clinical proteomics holds significant promise for identifying novel biomarkers for aging and associated chronic diseases.
  • Adherence to robust technological approaches, statistical methods, and large databases is essential for future success.
  • Continued research is expected to yield a substantial increase in disease-related proteomic data.